Organization (Academic)
Brown University
ClinicalTrials.gov lists Brown University as lead sponsor of 287 trials. It has 169 active development programs and 54 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 24 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 24 in 2026 and about 23 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 24 already registered with a 2026 start date: at the cutoff, 6 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts. 3 trials are registered to start in 2027 or later.
Logo Brown University, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Brown University: 287 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (228)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Substance-Related Disorders | 95 |
| Alcoholism | 37 |
| Anxiety Disorders | 30 |
| HIV Infections | 28 |
| Obesity | 28 |
Showing 5 of 228 disease areas.
Trials by start year as sponsor or collaborator (29)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 24 |
| 2025 | 23 |
| 2024 | 22 |
| 2023 | 40 |
| 2022 | 45 |
| 2021 | 40 |
| 2020 | 18 |
| 2019 | 44 |
| 2018 | 38 |
| 2017 | 27 |
Showing 10 of 29 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 33 trials still running at the 2026-10-09 snapshot; registered median of 28 months across 217 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (169)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Arm I Carboplatin, Paclitaxel, Pembrolizumab | Squamous Cell Carcinoma of Head and Neck | Phase 3 | 1 |
| Arm III Pembrolizumab | Head and Neck Neoplasms | Phase 3 | 1 |
| Arm III Pembrolizumab | Carcinoma, Squamous Cell | Phase 3 | 1 |
| Arm III Pembrolizumab | Squamous Cell Carcinoma of Head and Neck | Phase 3 | 1 |
| Arm I Carboplatin, Paclitaxel, Pembrolizumab | Carcinoma, Squamous Cell | Phase 3 | 1 |
Showing 5 of 169 active programs.
Approved assets (54)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Rasagiline | 1 |
| Naltrexone 50 Mg | 1 |
| HYDROXYUREA | 1 |
| Modafinil | 1 |
| NIVOLUMAB | 4 |
Showing 5 of 54 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 36% hit target (n=137) | 32% on time (n=139) |
Journals published in (403)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Trials | 17 |
| BMC public health | 14 |
| JAMA network open | 14 |
| PloS one | 13 |
| The New England journal of medicine | 13 |
Showing 5 of 403 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 291 | 96 | 2025-12-30 |
Financing and grant events (1,536)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-03-31 | NIH grant | 398,749 | Reporter |
| 2025-09-30 | NIH grant | 10,781 | Reporter |
| 2025-09-26 | NIH grant | 583,716 | Reporter |
| 2025-09-25 | NIH grant | 2,150,570 | Reporter |
| 2025-09-23 | NIH grant | 179,869 | Reporter |
Showing 5 of 1,536 events.
Organization relationships (50)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| The Miriam Hospital | Co sponsors trial with | 14 |
| University of Texas | Co sponsors trial with | 2 |
| South African Medical Research Council | Co sponsors trial with | 2 |
| The Fenway Institute | Co sponsors trial with | 2 |
| University of Alabama, Tuscaloosa | Co sponsors trial with | 2 |
Showing 5 of 50 relationships.
Latest dated events (2,342)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-02-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 2,342 events.
CLIA clinical laboratory certificates (1)
| Lab | Certificate | Status |
|---|---|---|
| BROWN UNIVERSITY | Certificate of waiver | Terminated |
Biomarker capability evidence (486)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| A1CF | Trial sponsor | Named in trial inclusion criteria |
| ABCD1 | Trial sponsor | Named in trial inclusion criteria |
| ABCD1 | Trial sponsor | Named in trial inclusion criteria |
| AFP | Trial sponsor | Named in trial inclusion criteria |
| AHR | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 486 evidence rows.
Biomarkers this organization publishes on (917)
Shown in this order: most publications first.
Showing 5 of 917 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, and workforce and board diversity, as filed.